Yes, Give Aspirin Now
Based on the clinical scenario provided (intracerebral hemorrhage excluded, platelets >100 × 10⁹/L, INR ≤1.7, BP <185/110 mmHg), you should administer aspirin for acute ischemic stroke within 24-48 hours of symptom onset. 111
Key Decision Points
The 2018 AHA/ASA Guidelines provide a Class I, Level A recommendation for aspirin administration in acute ischemic stroke patients within 24-48 hours after onset 111. This is the strongest possible recommendation grade, supported by two large clinical trials and confirmed by Cochrane review.
Dosing Guidance
- Dose range: 160-300 mg (guidelines removed the specific "325 mg" recommendation because supporting trials used doses in this range) 111
- If patient cannot swallow: use rectal or nasogastric administration 111
Critical Timing Considerations
If the patient received IV alteplase (tPA):
- Generally delay aspirin for 24 hours after thrombolysis 111
- Exception: May give earlier if there's a concomitant condition where withholding aspirin poses substantial risk (e.g., recent coronary stent) 111
If the patient did NOT receive IV alteplase:
Important Caveats
What Aspirin Cannot Replace
Aspirin is NOT a substitute for acute stroke treatments (Class III: No Benefit recommendation). Do not give aspirin instead of IV alteplase or mechanical thrombectomy in eligible patients 111. The question assumes these acute interventions have already been considered.
Safety Profile in Context
While research shows aspirin carries a small increased risk of intracranial hemorrhage in primary prevention settings (approximately 0.2 events per 1000 patient-years) 23, the benefit-risk ratio in secondary prevention after acute ischemic stroke is clearly favorable 111. The parameters you've confirmed (hemorrhage excluded, adequate platelets, controlled INR and BP) address the key safety concerns.
Minor Stroke Consideration
If this is a minor stroke or high-risk TIA, consider dual antiplatelet therapy (aspirin + clopidogrel for 21 days) instead of aspirin alone, as this provides additional benefit for early secondary stroke prevention up to 90 days (Class IIa recommendation) 111.
Contraindications to Verify
Before administering, confirm no: